Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2025)

Historic FCF Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 781.46%.

  • Monte Rosa Therapeutics' FCF Margin rose 10135900.0% to 781.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.89%, marking a year-over-year increase of 4991600.0%. This contributed to the annual value of 50.26% for FY2024, which is N/A changed from last year.
  • Monte Rosa Therapeutics' FCF Margin amounted to 781.46% in Q3 2025, which was up 10135900.0% from 157.0% recorded in Q2 2025.
  • Monte Rosa Therapeutics' FCF Margin's 5-year high stood at 781.46% during Q3 2025, with a 5-year trough of 3717.01% in Q1 2024.